Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company specializing in treatments for hypertension, chronic kidney disease (CKD), and obstructive sleep apnea (OSA), has scheduled its Q1 2025 financial results announcement for Monday, May 12, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET to discuss the results. Investors can access the call via domestic (1-800-717-1738) or international (1-646-307-1865) numbers using Conference ID 53214. A live webcast will be available through the Investor Relations section of the company's website.

News Market Reaction

-7.49%

1 alert

-7.49% News Effect

On the day this news was published, MLYS declined 7.49%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

05/05/2025 - 04:05 PM

RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2025, after the financial markets close on Monday, May 12, 2025.

*Monday, May 12*^th @ 4:30 p.m. ET
Domestic:	1-800-717-1738
International:	1-646-307-1865
Conference ID:	53214
Webcast:	Link

A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.

About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.

Contact:

Investor Relations
investorrelations@mineralystx.com

Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com

FAQ

When will Mineralys Therapeutics (MLYS) report Q1 2025 earnings?

Mineralys Therapeutics will report Q1 2025 earnings on Monday, May 12, 2025, after market close.

How can I join the Mineralys Therapeutics Q1 2025 earnings call?

You can join via phone (US: 1-800-717-1738, International: 1-646-307-1865, Conference ID: 53214) or through the webcast available on the company's Investor Relations website at 4:30 p.m. ET.

What diseases does Mineralys Therapeutics (MLYS) focus on treating?

Mineralys Therapeutics focuses on developing medicines for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other diseases driven by dysregulated aldosterone.